BRAF and neoplasm: Moreover, it is not obvious that a mutated gene that behaves as a driver in a context does act similarly in a different tumor, as shown by the V600E BRAF mutants that respond to BRAF inhibitors in 80% of melanomas but only in 5% of colon cancers [90–92].